1-Isocyanato-cyclobutanecarboxylic acid ethyl ester | 106366-62-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Isocyanato-cyclobutanecarboxylic acid ethyl ester
• 英文别名: Ethyl 1-isocyanatocyclobutane-1-carboxylate
• CAS: 106366-62-5
• 化学式: C₈H₁₁NO₃
• mdl: MFCD23144192
• 分子量: 169.18
• InChiKey: WBEFTWIDTCMAOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Isocyanato-cyclobutanecarboxylic acid ethyl ester 450.0 ℃ 、13.33 Pa 条件下， 生成 7-氧杂-5-氮杂螺[3.4]辛烷-6,8-二酮
  参考文献：
  名称：

  1-碳乙氧基-1,1-三亚甲基-3-重氮-2-丙酮的新型扩环

  摘要：

  标题化合物经历不寻常的热环丁基到环戊基的重排，这是由就地产生的具有悬垂官能团的乙烯酮部分的分子内反应引发的。

  DOI：

  10.1016/s0040-4039(00)84552-9
• 作为产物：
  描述：

  1-Azidocarbonyl-cyclobutanecarboxylic acid ethyl ester 以 甲苯 为溶剂， 生成 1-Isocyanato-cyclobutanecarboxylic acid ethyl ester
  参考文献：
  名称：

  1-碳乙氧基-1,1-三亚甲基-3-重氮-2-丙酮的新型扩环

  摘要：

  标题化合物经历不寻常的热环丁基到环戊基的重排，这是由就地产生的具有悬垂官能团的乙烯酮部分的分子内反应引发的。

  DOI：

  10.1016/s0040-4039(00)84552-9

文献信息

• Cyclic hydrazine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06281363B1

  公开（公告）日：2001-08-28

  Hydrazine derivatives and their pharmaceutically acceptable salts useful for the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular disease, fever, hemorrhage, and sepsis.

  肼衍生物及其药用可接受盐，用于治疗炎症和自身免疫性疾病、骨关节炎、呼吸系统疾病、肿瘤、消瘦症、心血管疾病、发热、出血和败血症。
• MILLER R. D.; THEIS W., TETRAHEDRON LETT., 27,(1986) N 22, 2447-2450
  作者：MILLER R. D.、 THEIS W.

  DOI：——

  日期：——
• CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1137640A1

  公开（公告）日：2001-10-04
• US6281363B1
  申请人：——

  公开号：US6281363B1

  公开（公告）日：2001-08-28
• [EN] CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS<br/>[FR] DERIVES CYCLIQUES DE L'HYDRAZINE COMME INHIBITEURS TNF-ALPHA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2000035885A1

  公开（公告）日：2000-06-22

  Hydrazine derivatives of formula (I) wherein W represents O, S, CO, NR?5, (CR3R4)¿m, or CR11; X represents CO, NR6, (CH2)n, CR?12 or CHR13¿; Y represents CO, NR7, (CH2)p, or CHR14; Z represents CO, CS, SO¿2?, or CH2; m stands for 0 or 1; n and p each individually stand for 0, 1, or 2; R?1¿ represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula V-aryl, V-heterocyclyl or -(CH¿2?)q-CH=CR?8R9; R3, R4, R5, R6 and R7¿ each independently represent hydrogen, optionally substituted lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl, aryl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl; or R?3 and R4¿ together with the carbon atom to which they are attached form a 3- to 8-membered ring; or R?5 and R6 or R5 and R7¿ together with the nitrogen atoms to which they are attached form a 3- to 8-membered ring; or R?11 and R12¿ together with the sp2 carbon atoms to which they are attached form a fused lower cycloalkenyl, aryl or heteroaryl ring; or R5 with either R?13 or R14¿ together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; or either R?6 or R7¿ with either R3 or R4 together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; or R?3 and R4¿ together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; V represents a spacer group; R?8 and R9¿ together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; and q stands for 1 or 2; with the provisos that (i) at least one of W, X and Y represents one of the heteroatoms previously indicated for these substituents or CO, (ii) Z represents CO or SO2 or CS when W represents O; (iii) W, X, Y and Z are not all CO and (iv) W, X and Y are not all NR?5, NR6 and NR7¿, respectively; and pharmaceutically acceptable salts thereof inhibit the release of tumour necrosis factor alpha (TNF-α) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumours, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.